Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 625–648 of 3,925 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: HTN Clear all
Terminated Phase 3 Interventional Results available

Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH)

NCT01117987
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2015 · Synced Nov 10, 2026, 2:43 PM EST
Completed Phase 2Phase 3 Interventional

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

NCT07354516
View directory record Official record
Conditions
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Interventions
QLS-111-FDC, Latanoprost (0.005%)
Combination Product · Drug
Lead sponsor
Qlaris Bio, Inc.
Industry
Eligibility
12 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Largo, Florida
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Nov 10, 2026, 2:43 PM EST
Recruiting Not applicable Interventional

Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-Substudy

NCT07781709
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Measurement of oxyhemoglobin and deoxyhemoglobin concentration pre and post- exercise at baseline and Week 12. Measurement of time to recovery of oxyhemglobin post-exercise at baseline and at Week 12., Blood draw
Device · Diagnostic Test
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 10, 2026 · Synced Nov 10, 2026, 2:43 PM EST
Completed Phase 2 Interventional Results available

Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension

NCT02178098
View directory record Official record
Conditions
Hypercholesterolemia, Hypertension
Interventions
ETC-1002, Placebo
Drug
Lead sponsor
Esperion Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
43
States / cities
Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Nov 10, 2026, 2:43 PM EST
Withdrawn Phase 4 Interventional

The Management of Resistant Hypertension in Kidney Transplant Patients Using Chlorthalidone

NCT02030314
View directory record Official record
Conditions
Resistant Hypertension in Kidney Transplant Patients
Interventions
Chlorthalidone
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 15, 2017 · Synced Nov 10, 2026, 2:43 PM EST
Not listed No phase listed Observational

Wrist Worn Blood Pressure Measurement

NCT03919136
View directory record Official record
Conditions
Blood Pressure, Heart Failure, Advanced Heart Failure, Heart Failure，Congestive
Interventions
Wrist-worn measurement device (LiveMetric)
Device
Lead sponsor
LiveMetric S.A.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
3
States / cities
Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 19, 2019 · Synced Nov 10, 2026, 2:43 PM EST
Completed No phase listed Observational

Intraocular Pressure During Robotic Assisted Laparoscopic Procedures Utilizing Steep Trendelenburg Positioning

NCT01261871
View directory record Official record
Conditions
Ocular Hypertension
Interventions
Not listed
Lead sponsor
United States Naval Medical Center, San Diego
Federal
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2016 · Synced Nov 10, 2026, 2:43 PM EST
Completed No phase listed Observational

Automated Measurement of Optic Nerve Sheath Diameter

NCT02786706
View directory record Official record
Conditions
Traumatic Brain Injury, Acute Brain Injuries, Intracranial Hypertension
Interventions
Optic nerve ultrasound
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 4, 2020 · Synced Nov 10, 2026, 2:43 PM EST
Not listed Phase 4 Interventional

Riociguat for Sarcoidosis Associated Pulmonary Hypertension

NCT02625558
View directory record Official record
Conditions
Sarcoidosis
Interventions
Riociguat, Placebo
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 9, 2015 · Synced Nov 10, 2026, 2:43 PM EST
Completed Not applicable Interventional Results available

RCT of Effects of Device-guided Breathing on Ambulatory BP

NCT01184755
View directory record Official record
Conditions
Hypertension
Interventions
Relaxation, RESPeRate
Behavioral · Device
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
2
States / cities
New Brunswick, New Jersey • New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Nov 10, 2026, 2:43 PM EST
Terminated Phase 3 Interventional Results available

A Trial to Determine the Efficacy and Safety of Presendin in IIH

NCT05347147
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Presendin, Placebo
Drug
Lead sponsor
Invex Therapeutics Ltd.
Industry
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Aurora, Colorado • Miami, Florida • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Nov 10, 2026, 2:43 PM EST
Completed Phase 3 Interventional Results available

One-Year Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00695955
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil with or without add-on chlorthalidone, Azilsartan medoxomil with or without add-on hydrochlorothiazide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
669 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Ozark, Alabama • Tallassee, Alabama • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Nov 10, 2026, 2:43 PM EST
Completed Not applicable Interventional

The Produce Drop: Using Food as Medicine to Lower A1C Levels and Blood Pressure

NCT04421755
View directory record Official record
Conditions
Diabetes, Hypertension, Nutrition Poor
Interventions
Produce delivery, Cooking classes
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 64 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Tulsa, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Nov 10, 2026, 2:43 PM EST
Completed Not applicable Interventional

ASPIRE: Adapting Self-Blood Pressure Monitoring to Reduce Health Disparities

NCT06175793
View directory record Official record
Conditions
Hypertension
Interventions
ASPIRE Intervention
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Oak Lawn, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Nov 10, 2026, 2:43 PM EST
Completed Phase 2 Interventional Results available

An Open-Label Extension of BPS-MR-PAH-201 in Pulmonary Arterial Hypertension (PAH) Patients

NCT00792571
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Beraprost Sodium Modified Release
Drug
Lead sponsor
Lung Biotechnology PBC
Industry
Eligibility
18 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
3
States / cities
Torrance, California • Pittsburgh, Pennsylvania • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Nov 10, 2026, 2:43 PM EST
Recruiting Not applicable Interventional

Right Ventricular Pacing in Pulmonary Arterial Hypertension

NCT04194632
View directory record Official record
Conditions
Pulmonary Artery Hypertension, Right Ventricular Dysfunction
Interventions
Temporary right ventricular pacing
Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 10, 2026, 2:43 PM EST
Terminated Not applicable Interventional Results available

EnligHTN IV Trial - Multicenter Sham-controlled RCT of Renal Denervation for Hypertension

NCT01903187
View directory record Official record
Conditions
Hypertension
Interventions
EnligHTN Renal Denervation, Sham
Device · Procedure
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Huntsville, Alabama • Little Rock, Arkansas • Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 10, 2026, 2:43 PM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Assessment of Risks of Perinephric Fat Thickness to Adverse Renal Outcomes Post Donor Nephrectomy

NCT06886087
View directory record Official record
Conditions
Living Kidney Donation, Hypertension, Nephrectomy
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Nov 10, 2026, 2:43 PM EST
Active, not recruiting No phase listed Observational

Sympathetic Activity in Post-injury Outcomes: Impact on Sleep and caRdiovascular Health InvesTigation

NCT05971433
View directory record Official record
Conditions
Hypertension, Cardiovascular Diseases, Sleep Disorder, Arrythmia, Sympathetic Nervous System, Injury Traumatic
Interventions
Not listed
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 10, 2026, 2:43 PM EST
Completed Not applicable Interventional Results available

Measuring Adherence to Control Hypertension

NCT01257347
View directory record Official record
Conditions
Hypertension
Interventions
Disclosure of adherence report to clinician, MedSignals pillbox
Behavioral · Device
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Nov 10, 2026, 2:43 PM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of PF-04217329 in Patients With Glaucoma or Elevated Eye Pressure.

NCT00572455
View directory record Official record
Conditions
Primary Open-Angle Glaucoma, Ocular Hypertension
Interventions
PF-04217329 - Lowest Dose, PF-04217329 - Low Dose, PF-04217329 - Middle Dose, PF-04217329 - High Middle Dose, PF-04217329 - High Dose, PF-4217329 - Highest Dose, PF-04217329 - Vehicle, Latanoprost Vehicle, Latanoprost 0.005%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
23
States / cities
Artesia, California • Newport Beach, California • Petaluma, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2021 · Synced Nov 10, 2026, 2:43 PM EST
Active, not recruiting Not applicable Interventional Results available

A Study of the ReCor Medical Paradise System in Clinical Hypertension

NCT02649426
View directory record Official record
Conditions
Hypertension, Vascular Diseases
Interventions
The Paradise® Renal Denervation Ultrasound System, Sham Procedure
Device
Lead sponsor
ReCor Medical, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
24
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 10, 2026, 2:43 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Genetic Testing to Understand and Address Renal Disease Disparities

NCT02234063
View directory record Official record
Conditions
Hypertension, Chronic Kidney Disease, Genomics
Interventions
Immediate Genetic Testing
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 65 Years
Enrollment
2,052 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2020 · Synced Nov 10, 2026, 2:43 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

Validation of Noninvasive Blood Pressure Device

NCT04676152
View directory record Official record
Conditions
Healthy, Hypertension, Hypotension
Interventions
Masimo Noninvasive Blood Pressure Device
Device
Lead sponsor
Masimo Corporation
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
2
States / cities
Irvine, California • Lomita, California
Source: ClinicalTrials.gov public record
Updated Jan 8, 2024 · Synced Nov 10, 2026, 2:43 PM EST